Pyoderma Gangrenosum Clinical Trial
Official title:
Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015
Pyoderma gangrenosum (PG) is a rare disease. She is often under diagnosed and a source of
diagnostic wandering and inadequate care. Moreover, its association in more than one case out
of two to a significant underlying pathology, such as inflammatory bowel disease,
inflammatory rheumatism, or hematology, makes its diagnosis essential. Its pathophysiological
mechanisms remain controversial and many other comorbidities have been reported in the
literature, including endocrinological, cardiovascular and metabolic, neoplastic and
autoimmune comorbidities.
The objective is to study the field, comorbidities and pathologies associated with PG on a
series of patients diagnosed with PG, as well as to characterize the clinical and
histological aspects of lesions.
A retrospective observational non-interventional multicenter study is proposed. 10 French
centers. The recruitment will be done via the DIM using coding software: codes L984 , L982
and L97 according to 2 major criteria (typical clinical appearance with ulceration well
limited and purulent or pustule hutches, exclusion of differential diagnoses) and at least 2
minor criteria (among compatible histological aspect, classically compatible associated
pathologies, corticosensitivity of lesions, pathergie phenomenon, painful lesions).
Demographic data, clinical appearance of the lesions, cardiovascular and metabolic
comorbidities, other associated pathologies, histological findings of the ulcer biopsy and
biological results to describe the population and associated pathologies or comorbidities to
PG
Pyoderma gangrenosum (PG) is a rare disease. She is often under diagnosed and a source of
diagnostic wandering and inadequate care. Moreover, its association in more than one case out
of two to a significant underlying pathology, such as inflammatory bowel disease,
inflammatory rheumatism, or hematology, makes its diagnosis essential. Its pathophysiological
mechanisms remain controversial and many other comorbidities have been reported in the
literature, including endocrinological, cardiovascular and metabolic, neoplastic and
autoimmune comorbidities.
The objective is to study the field, comorbidities and pathologies associated with PG on a
series of patients diagnosed with PG, as well as to characterize the clinical and
histological aspects of lesions.
A retrospective observational non-interventional multicenter study is proposed. 10 French
centers. The recruitment will be done via the DIM using coding software: codes L984 (chronic
skin ulceration), L982 (febrile neutrophilic dermatosis) and L97 (leg ulcer) according to 2
major criteria (typical clinical appearance with ulceration well limited and purulent or
pustule hutches, exclusion of differential diagnoses) and at least 2 minor criteria (among
compatible histological aspect, classically compatible associated pathologies,
corticosensitivity of lesions, pathergie phenomenon, painful lesions).
Demographic data, clinical appearance of the lesions, cardiovascular and metabolic
comorbidities, other associated pathologies, histological findings of the ulcer biopsy and
biological results to describe the population and associated pathologies or comorbidities to
PG
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06092216 -
Spesolimab in Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT03311464 -
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
|
Phase 3 | |
Recruiting |
NCT04901325 -
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
|
Phase 2 | |
Completed |
NCT00791557 -
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
|
N/A | |
Terminated |
NCT02315417 -
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
|
Phase 3 | |
Terminated |
NCT02318914 -
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
|
Phase 3 | |
Completed |
NCT03137160 -
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Not yet recruiting |
NCT05984654 -
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
|
N/A | |
Completed |
NCT04895566 -
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
|
Early Phase 1 | |
Withdrawn |
NCT04274166 -
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT01882504 -
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Withdrawn |
NCT00730717 -
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT03971643 -
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
|
Phase 2 | |
Not yet recruiting |
NCT04792957 -
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
|
||
Not yet recruiting |
NCT05821374 -
Deucravacitinib in PG
|
Early Phase 1 | |
Terminated |
NCT03072953 -
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
|
Phase 2 | |
Recruiting |
NCT05120726 -
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
|
Phase 4 | |
Withdrawn |
NCT00690846 -
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT01965613 -
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
|
Phase 2 | |
Recruiting |
NCT01952275 -
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
|
N/A |